The latest announcement is out from Geron ( (GERN) ).
Geron Corporation has secured $250 million in funding through a loan agreement with Pharmakon Advisors and a synthetic royalty deal with Royalty Pharma, strengthening its financial position. This includes a $125 million loan tranche and $125 million from Royalty Pharma for tiered royalties on U.S. sales of RYTELO. Geron’s strong Q3 performance, with $28.2 million in RYTELO sales, underscores its commercial potential, supported by the company’s strategic investments and leadership changes to drive future growth in the biopharmaceutical sector.
For a thorough assessment of GERN stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend
- Amazon Considers Additional Multi-Billion Dollar Investment in Anthropic
- Will Palantir Stock Crash by 50%? Here’s What Jefferies Expects
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
